BioInvent - translating cancer antibody biology into innovative immuno-oncology therapies.
Based on its insights in immunology, cancer biology and antibody biology, BioInvent aims to develop cancer immunotherapies to improve the quality of life for cancer patients.
BioInvent's current operational activities are focused on:
- Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of hematological cancers, and in combination with pembrolizumab in solid cancer.
- Developing pre-clinical first-in-class antibodies targeting tumor-associated myeloid cells in collaboration with Pfizer.
- Advancing two compounds into clinical programs in solid cancer;
BI-1607 (an anti-FcγRllB antibody) in combination with a checkpoint inhibitor – projected start phase l proof of concept trial in H2 2019, and BI-1808 (an anti-TNFR2 antibody), as single agent and in combination with an anti-PD1 antibody – projected start phase l in H1 2020.
- Developing, in collaboration with Transgene, oncolytic viruses encoding either a validated anti-CTLA-4 antibody sequence, or antibody sequences targeting undisclosed targets for the treatment of solid tumors. Anti-CTLA-4/oncolytic virus – projected start phase I/Ila in H2 2020.
Immuno-oncology drugs can revolutionise treatment of cancer
The body’s immune system detects and destroys bacteria and viruses that would otherwise harm our organs and tissues. However, the immune system also has the potential to protect us from and fight cancer. Unfortunately, many tumour cells have the ability to manipulate important cells in our immune system in order to continue to multiply.
While chemotherapy is aimed directly at the tumour cells, immuno-oncology drugs activate important cells in the immune system (especially T-cells), and stimulate them to attack tumours. Immuno-oncology drugs are one of the greatest breakthroughs of the twenty-first century in the field of medicine.
They are making an important contribution in transforming the treatment of cancer through significant improvements in survival rates. However currently available immune modulatory drugs are only able to help a fraction of all cancer patients. Commercially, immuno-oncology therapies are expected to continue to be a success, with estimated sales to exceed USD 40 billion by 2022, according to the Cowen 2017 Therapeutic Categories report.
There are checkpoints on the surface of immune cells, which act as a switch for inactivating the immune system. In some cases, cancer cells manipulate these proteins to avoid attacks.
For the past few years, immuno-oncology drugs that are capable of blocking the checkpoint receptors PD-1 and CTLA-4 and also the ligand PD-L1 have been used. They have produced good treatment results in certain types of solid tumors and achieved great commercial success, but unfortunately they only help a minority of patients with metastatic cancer. Consequently, intense efforts are underway to develop new drugs that can complement the checkpoint inhibitors.
BioInvent is developing antibodies specifically targeting regulatory T cells and tumor-associated myeloid cells, both of which are strongly immunosuppressive, and Fcγ receptors. All these approaches have synergy effects when combined with the checkpoint inhibitors available today.
Five focus areas for our value creation
BioInvent’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives. This is accomplished through collaborations with large pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
Five focus areas are deemed essential to the Company’s continued success – high-level science, professional product development, commercial focus, sound risk management and financing.